The Role of Product Development Process in the Future Value of Medicines

Wednesday, November 15, 2017 7 PM
CLU Gilbert Sports and Fitness Center, 130 Overton Court, rooms 253/254 (second floor)

Biomedical startups are very different than tech startups since they attempt to develop a solution for unmet medical needs 10-15 years in the future. Likewise, the cost of new drug development is now estimated at $2.6 billion with a success rate of only 5% for drugs making it to the clinic. How can we get improved therapies to market at a lower risk and cost?

This presentation provides insight into how entrepreneurs, big companies, and investors, improve the clinical and financial value of drugs in their pipelines. By anticipating future changes in clinical practice and competitive choices, developers of new products clinically test potential features of a product that may provide meaningful differentiation for patients and payers. These choices also provide ways to improve returns and reduce risk during the long and expensive clinical development path. Whether the product is a pharmaceutical, device, or diagnostic, thoughtful product development can greatly improve the chance that useful new products make it to the market.

Michael Reilly

Michael Reilly is the CEO and Co-Founder of Excelse Bio, a privately held company developing high concentration biotechnology medicines. He continues to serve as VP of Business Development at Integrity Bio, a biotechnology formulation services firm affiliated with Excelse Bio.

Michael has 30 years of international leadership experience in marketing, business development, strategy, and finance at Amgen, Baxter, Sanofi, Sterling Drug, and Eastman Kodak. Previous startups include Attentive Therapeutics where he co-invented a new medication for ADHD which has recently completed a successful controlled clinical trial. Previously, Michael was Head of Strategy and member of the Senior Management Team at Baxter BioScience. He was the commercial lead for Amgen's acquisition of Immunex and its drug Enbrel, the largest in biotech history at $16B. As Global Commercial Leader at Amgen, he led denosumab (PROLIA, XGEVA) and several other Product Strategy Teams for Rheumatoid Arthritis, Alzheimer's, Parkinson's Disease and Cancer.

Michael earned a Master's degree from the Ross School of Business at the University of Michigan in Ann Arbor, and a Bachelor's degree in Molecular Biology from the University of California, Berkeley.